サマリー

アジア太平洋地域の水頭症市場は、2023年の293,372.44千米ドルから2031年には539,658.18千米ドルに達すると予測され、2024年から2031年の予測期間における年平均成長率は8.1%である。

市場セグメント
アジア太平洋地域の水頭症市場：タイプ別（先天性水頭症、後天性水頭症、正常圧水頭症、外水頭症）、診断・治療別（診断と治療）、エンドユーザー別（病院、診療所、診断センター、学術機関・研究機関）、国別（中国、日本、インド、韓国、オーストラリア、シンガポール、タイ、マレーシア、インドネシア、フィリピン、アジア太平洋地域その他）-産業動向と2031年までの予測
アジア太平洋水頭症市場ダイナミクスの概要

促進要因
- 神経疾患の発生率の増加
抑制要因

- 不十分な償還政策

機会

- 医療機関や政府機関による支援の拡大

市場プレイヤー

アジア太平洋地域の水頭症市場で事業を展開する主な市場参入企業は以下の通り：

- B. Braun傘下のAesculap, Inc.
- インテグラ・ライフサイエンス
- ジー・サーギウェア
- モレール・メディカル社
- アヌンシア社
- クリストフ・ミースケGmbH & co.KG
- KARL STORZ SE & Co.KG
- 株式会社プロテテス
- メドトロニック
- ナタス
- デスーメディカル
- ビカクシラー
- シュピーゲルベルグGmbH & Co.KG
- ソフィサ
- カネカメディックス

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 31
1.1 OBJECTIVES OF THE STUDY 31
1.2 MARKET DEFINITION 31
1.3 OVERVIEW OF ASIA PACIFIC HYDROCEPHALUS MARKET 31
1.4 LIMITATIONS 32
1.5 MARKETS COVERED 32
2 MARKET SEGMENTATION 35
2.1 MARKETS COVERED 35
2.2 GEOGRAPHICAL SCOPE 36
2.3 YEARS CONSIDERED FOR THE STUDY 37
2.4 CURRENCY AND PRICING 37
2.5 DBMR TRIPOD DATA VALIDATION MODEL 38
2.6 MULTIVARIATE MODELLING 41
2.7 TYPE LIFELINE CURVE 41
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42
2.9 DBMR MARKET POSITION GRID 43
2.10 VENDOR SHARE ANALYSIS 44
2.11 SECONDARY SOURCES 45
2.12 ASSUMPTIONS 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 48
5 ASIA PACIFIC HYDROCEPHALUS MARKET: REGULATIONS 49
5.1 REGULATIONS IN U.S. 49
5.2 REGULATIONS IN EUROPE 49
5.3 REGULATIONS IN INDIA 49
5.4 REGULATIONS IN JAPAN 50
5.5 REGULATIONS IN BRAZIL 50
6 MARKET OVERVIEW 51
6.1 DRIVERS 53
6.1.1 INCREASING INCIDENCE OF NEUROLOGICAL CONDITIONS 53
6.1.2 GROWING NUMBER OF NEW-BORNS AFFECTED BY HYDROCEPHALUS 53
6.1.3 INCREASING ADAPTATION OF ADVANCED PROGRAMMABLE VALVES 54
6.1.4 RISING AWARENESS ABOUT HYDROCEPHALUS 54
 
6.2 RESTRAINTS 55
6.2.1 POOR REIMBURSEMENT POLICIES 55
6.2.2 DELETERIOUS COMPLICATIONS WITH HYDROCEPHALUS DEVICES 55
6.3 OPPORTUNITIES 56
6.3.1 GROWING SUPPORT BY HEALTHCARE ORGANIZATIONS AND GOVERNMENT BODIES 56
6.3.2 GROWING HEALTHCARE EXPENDITURE 57
6.3.3 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYERS 57
6.4 CHALLENGES 58
6.4.1 HIGH PRODUCT RECALL SCENARIO 58
6.4.2 LACK OF ACCESSIBILITY OF HYDROCEPHALUS PRODUCTS 58
7 ASIA PACIFIC HYDROCEPHALUS MARKET, BY TYPE 59
7.1 OVERVIEW 60
7.2 CONGENITAL HYDROCEPHALUS 63
7.3 ACQUIRED HYDROCEPHALUS 63
7.4 NORMAL-PRESSURE HYDROCEPHALUS 64
7.5 EX-VACUO HYDROCEPHALUS 64
8 ASIA PACIFIC HYDROCEPHALUS MARKET, BY DIAGNOSTICS & TREATMENT 65
8.1 OVERVIEW 66
8.2 DIAGNOSTICS 69
8.2.1 MAGNETIC RESONANCE IMAGING (MRI) 69
8.2.2 CT SCAN – HEAD 69
8.2.3 HEAD ULTRASOUND 70
8.3 TREATMENT 70
8.3.1 SURGERY – SHUNT INSERTION, BY PRODUCT TYPE 71
8.3.1.1 HYDROCEPHALUS VALVES 71
8.3.1.2 HYDROCEPHALUS CATHETERS 71
8.3.1.2.1 ADJUSTABLE PRESSURE VALVES 71
8.3.1.2.2 FIX PRESSURE VALVES 72
8.3.2 SURGERY – SHUNT INSERTION, BY AGE GROUP 72
8.3.2.1 PEDIATRIC 72
8.3.2.2 ADULT 72
8.3.3 VENTRICULOSTOMY 72
8.3.4 MEDICATION 72
8.3.5 TREATMENT, BY AGE GROUP 73
8.3.6 INFANTS 73
8.3.7 CHILDREN 73
8.3.8 ADULTS 73
 
9 ASIA PACIFIC HYDROCEPHALUS MARKET, BY END USERS 74
9.1 OVERVIEW 75
9.2 HOSPITALS 78
9.3 CLINICS 78
9.4 DIAGNOSTIC CENTERS 79
9.5 ACADEMIC INSTITUTIONS AND RESEARCH ORGANIZATIONS 79
9.5.1 HOSPITALS 80
9.5.2 AMBULATORY AND SURGICAL CENTERS 80
9.5.3 HOSPITALS 80
9.5.4 CLINICS 80
9.5.5 DIAGNOSTIC CENTER 81
9.5.6 SURGICAL CENTERS 81
9.5.7 AMBULATORY SURGICAL CENTERS 81
9.5.8 OTHERS 81
10 ASIA PACIFIC HYDROCEPHALUS MARKET, BY REGION 82
10.1 ASIA-PACIFIC 84
10.1.1 JAPAN 89
10.1.2 CHINA 93
10.1.3 SOUTH KOREA 97
10.1.4 INDIA 101
10.1.5 AUSTRALIA 105
10.1.6 SINGAPORE 109
10.1.7 THAILAND 113
10.1.8 MALAYSIA 117
10.1.9 INDONESIA 121
10.1.10 PHILIPPINES 125
10.1.11 VIETNAM 129
10.1.12 REST OF ASIA-PACIFIC 133
11 ASIA PACIFIC HYDROCEPHALUS MARKET, COMPANY LANDSCAPE 134
11.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 134
12 SWOT ANALYSIS 135
 
13 COMPANY PROFILE 136
13.1 MEDTRONIC 136
13.1.1 COMPANY SNAPSHOT 136
13.1.2 REVENUE ANALYSIS 136
13.1.3 COMPANY SHARE ANALYSIS 137
13.1.4 PRODUCT PORTFOLIO 137
13.1.5 RECENT DEVELOPMENTS 137
13.2 AESCULAP, INC. – A B. BRAUN COMPANY 138
13.2.1 COMPANY SNAPSHOT 138
13.2.2 COMPANY SHARE ANALYSIS 138
13.2.3 PRODUCT PORTFOLIO 139
13.2.4 RECENT DEVELOPMENT 139
13.3 INTEGRA LIFESCIENCES 140
13.3.1 COMPANY SNAPSHOT 140
13.3.2 REVENUE ANALYSIS 140
13.3.3 COMPANY SHARE ANALYSIS 141
13.3.4 PRODUCT PORTFOLIO 141
13.3.5 RECENT DEVELOPMENT 142
13.4 SPIEGELBERG GMBH & CO. KG 143
13.4.1 COMPANY SNAPSHOT 143
13.4.2 COMPANY SHARE ANALYSIS 143
13.4.3 PRODUCT PORTFOLIO 144
13.4.4 RECENT DEVELOPMENT 144
13.5 BICAKCILAR 145
13.5.1 COMPANY SNAPSHOT 145
13.5.2 COMPANY SHARE ANALYSIS 145
13.5.3 PRODUCT PORTFOLIO 146
13.5.4 RECENT DEVELOPMENTS 146
13.6 ANUNCIA INC 147
13.6.1 COMPANY SNAPSHOT 147
13.6.2 PRODUCT PORTFOLIO 147
13.6.3 RECENT DEVELOPMENT 147
13.7 CHRISTOPH MIETHKE GMBH & CO. KG 148
13.7.1 COMPANY SNAPSHOT 148
13.7.2 PRODUCT PORTFOLIO 148
13.7.3 RECENT DEVELOPMENT 149
 
13.8 DESU MEDICAL 150
13.8.1 COMPANY SNAPSHOT 150
13.8.2 PRODUCT PORTFOLIO 150
13.8.3 RECENT DEVELOPMENT 150
13.9 G.SURGIWEAR LTD 151
13.9.1 COMPANY SNAPSHOT 151
13.9.2 PRODUCT PORTFOLIO 151
13.9.3 RECENT DEVELOPMENT 151
13.10 HPBIO 152
13.10.1 COMPANY SNAPSHOT 152
13.10.2 PRODUCT PORTFOLIO 152
13.10.3 RECENT DEVELOPMENT 152
13.11 KANEKA MEDIX CORP 153
13.11.1 COMPANY SNAPSHOT 153
13.11.2 REVENUE ANALYSIS 153
13.11.3 PRODUCT PORTFOLIO 155
13.11.4 RECENT DEVELOPMENTS 155
13.12 KARL STORZ SE & CO. KG 156
13.12.1 COMPANY SNAPSHOT 156
13.12.2 PRODUCT PORTFOLIO 156
13.12.3 RECENT DEVELOPMENT 156
13.13 MÖLLER MEDICAL GMBH 157
13.13.1 COMPANY SNAPSHOT 157
13.13.2 PRODUCT PORTFOLIO 157
13.13.3 RECENT DEVELOPMENT 157
13.14 NATUS MEDICAL INCORPORATED 158
13.14.1 COMPANY SNAPSHOT 158
13.14.2 PRODUCT PORTFOLIO 158
13.14.3 RECENT DEVELOPMENTS 159
13.15 SOPHYSA 160
13.15.1 COMPANY SNAPSHOT 160
13.15.2 PRODUCT PORTFOLIO 160
13.15.3 RECENT DEVELOPMENTS 161
14 QUESTIONNAIRE 162
15 RELATED REPORTS 165